The potential antioxidant effect of raloxifene treatment: A study on heart, liver and brain cortex of ovariectomized female rats

Cell Biochemistry and Function

Volumn 25, Issue 3, 2007, Pages 259-266

  Konyalioglu, Sibel ^a   Durmaz, Guliz ^a   Yalcin, Ayfer ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Antioxidant enzymes; Glutathione; Lipid peroxidation; Ovariectomy; Raloxifene; Selective estrogen receptor modulators

Indexed keywords

CARBOXYMETHYLCELLULOSE; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RALOXIFENE; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; HEART; LIVER; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIOXIDANTS; CATALASE; CEREBRAL CORTEX; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEART; LIVER; MALONDIALDEHYDE; OVARIECTOMY; OXIDATIVE STRESS; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; THIOREDOXIN-DISULFIDE REDUCTASE;

ANIMALIA; RATTUS;

EID: 34249681382     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1328     Document Type: Article

References (37)

1. Galli F, Piroddi M, Annetti C, Aisa C, Floridi E, Floridi A. Oxidative stress and reactive oxygen species. Contrib Nephrol 2005; 149: 240-260.
2. Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bidzinska B, Milewicz A, Antonowicz-Juchniewicz J, Andrzejak R. Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and postmenopausal women. Gynecol Endocrinol 2001; 15: 298-303.
3. Ozgonul M, Oge A, Sezer ED, Bayraktar F, Sozmen EY. The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovarectomized female rats. Endocr Res 2003; 29: 183-189.
4. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, endothelial function. Womens Health Issues 2001; 11: 95-102.
5. Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, Ulukaya E. Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. Maturitas 2005; 50: 182-188.
6. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9: 1-160.
7. Bernardi F, Pluchino N, Stornati M, Pieri M, Genazzani AR. CNS: sex steroids and SERMs. Ann NY Acad Sci 2003; 997: 378-388.
8. Mitlak BH, Cohen FJ. In search of optimal long-term female estrogen replacement: the potential of selective estrogen receptor modulators. Hor Res 1997; 48: 155-163.
9. Purdie DW, Beardsworth SA. The selective estrogen receptor modulation: evaluation and clinical application. Br J Clin Pharmacol 1999; 48: 785-792.
10. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium is postmenopausal women. N Eng J Med 1997; 337: 1641-1647.
11. Kume-Kick J, Ferris DC, Russo-Menna I, Rice ME. Enhanced oxidative stress in female rat brain after gonadectomy. Brain Res 1996; 738: 8-14.
12. Strehlow K, Rotter S, Wassmann S, et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003; 93: 170-177.
13. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypercholesterolemic activity of raloxifene (LY139481): Pharmacological characterzation as a selective estrogen receptor modulator. J Pharmacol ExpTher 1997; 280(1): 146-153.
14. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-126.
15. Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci USA 1996; 93: 1006-1011.
16. Marini H, Altavilla D, Bellomo M, et al. Modulation of IL-1 beta gene expression by lipid peroxidation inhibition after kainic acid-induced rat brain injury. Exp Neurol 2004; 188: 178-186.
17. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37-43.
18. Yagi K. LPO assay for blood plasma or serum. Meths Enzymol 1984; 105: 328-331.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
21. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
22. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.
23. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005; 66: 295-306.
24. Powis G, Oblong JE, Gasdaska PY, Berggren M, Hill SR, Kickparick DL. The thioredoxin/ thioredoxin reductase redox system and control of cell growth. Oncol Res 1994; 6: 539-544.
25. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidation and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44: 381-386.
26. Persky AM, Green PS, Stubley L, et al. Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro. Proc Soc Exp Biol Med 2000; 223: 59-66.
27. Hernandez I, Delgado JL, Diaz J, et al. 17-beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2000; 279: 1599-1605.
28. Prediger ME, Gamaro GD, Crema LM, Fontella FU, Dalmaz C. Estradiol protects against oxidative stress induced by chronic variate stress. Neureichem Res 2004; 29: 1923-1930.
29. Gordon KB, Macrae IM, Carswell HV. Effects of 17-beta estradiol on cerebral ischaemic damage and lipid peroxidation. Brain Res 2005; 1036: 155-162.
30. Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifene, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002; 76: 214-222.
31. Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T. Estrogen like activity of tamoxifen and raloxifen on NMDA receptor binding and expression of subunits in rat brain. Neuropsychopharmacology 2001; 25: 242-257.
32. Zhou W, Koldzic-Zivanovic N, Clarke CH, et al. Selective estrogen receptor modulator effects in the rat brain. Neuroendocrinology 2002; 75(1): 24-33.
33. Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR. CNS: Sex steroids and SERMs. Ann NY Acad Sci 2003; 997: 378-388.
34. O'Neill K, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outhgrowth following toxic insults associated with aging and Alzheimer 's disease. Exp Neurol 2004; 185: 63-80.
35. Yalcin A, Kanit L, Durmaz G, Sargin S, Terek CH, Tanyolac B. Altered level of apurinic/apyrimidinic endonuclease/redox factor-1 (APE/Ref-1) mRNA in the hippocampus of ovariectomized rats treated by raloxifene against kainic acid. Clin Exp Pharm Physiol 2005; 32: 611-614.
36. Oge A, Sezer ED, Ozgonul M, Bayraktar F, Sozmen EY. The effects of estrogen and raloxifene treatment on the antioxidant enzymes and nitrite-nitrate levels in brain cortex of ovariectomized rats. Neurosci Lett 2003; 338: 217-220.
37. Chiueh C, Lee S, Andoh T, Murphy D. Induction of antioxidative and antiapoptotic thioredoxin supports neuroprotective hypothesis of estrogen. Endocrine 2003; 21: 27-31.